APUS
APIMEDS PHARM (APUS)
NYSE
$0.73-$0.003 (-0.41%)
Price as of Jul 13, 2026 7:47 PM EDT
  • $10.9M
    Market Cap
  • -95.99%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: N/A
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

APUS Investors Have Opportunity to Join Apimeds Pharmaceuticals US, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm is investigating Apimeds Pharmaceuticals US, Inc. (APUS), Elite Express Holding Inc. (ETS), and Decent Holding Inc. (DXST) for potential securities law violations, including allegations of false statements and failure to disclose material information to investors. Affected shareholders are encouraged to participate in the investigation.

04/26/2026, 8:12 PM • GlobeNewswire

Peers

Statistics

More
Day Range
$0.71
$0.74
$0.74
1-Year Range
$0.72
$3.90
$0.74
Latest Close$0.74
Change
+$0.02 (+2.31%)
Volume63,431
Market Cap$10.9M
Shares Outstanding15.1M
P/E (TTM)-0.23
Diluted EPS (TTM)-$3.18
Enterprise Value$18.1M

Information as of 07/13/2026

Company Profile

APIMEDS PHARMACEUTICALS US INC
APIMEDS PHARMACEUTICALS US INC
https://www.mindwavedao.com
$10.9M
Market Cap
-$40.7M
Net Income
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
100 Matawan Rd, Matawan, NJ, United States, 07747
848 201 5010

Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.

Key Executives

  • Erik C. Emerson
  • Christopher Kim
  • Erick J. Frim
  • Sungjoon Chae
  • Captain Sandeep Yadav

Current Ownership Distribution

  • Institutions448,756 (35.68%)
  • Mutual Funds315,813 (25.11%)
  • Insiders268,000 (21.31%)
  • Other225,029 (17.89%)